**KWF Kankerbestrijding**

Long-Term Programme Biomarkers 2025

**Checklist**

*The purpose of this checklist is to make a good assessment of whether you meet the criteria of the long-term programme. Before starting, carefully read the instructions below:*

1. *A checklist evaluated by KWF is required to participate in the programme.*
2. *You can* ***submit the checklist at anytime between the 3rd of September till 22nd of Oktober 2024, 12.00 CET as pdf file to*** ***biomarkers@kwf.nl******.*** *We advise to submit the checklist as soon as possible, as this will leave more time to work on the pre-proposal.*
3. *The checklist will be evaluated within 2 weeks. If your project is in scope, you will receive an invitation to submit a pre-proposal in GMS (****deadline for pre-proposals****:* ***3 December 2024, 12.00 CET****). If your project is not in scope, you will receive a justification why it is not a fit and whether another KWF call might be a better choice (if applicable).*
4. *For any questions, please contact* *biomarkers@kwf.nl**.*

**Eligibility**

*Please tick the boxes if applicable:*

[ ]  Biomarker development in/entering/higher than technology readiness level (TRL) 7.

[ ]  Single intended context-of-use of the biomarker, i.e. either (early)detection or diagnosis or prognosis or patient selection.

[ ]  Biomarker validation in independent cohort is completed.

[ ]  Biomarker characteristics are determined (selectivity, sensitivity).

[ ]  Multidisciplinary consortium experienced in development and commercialization (*if applicable*) and implementation of the biomarker.

**Project Details**

*Please provide the requested information:*

Project leader (name, department, institute):

Title of Project:

Intended run time (months):

**Brief summary**

|  |
| --- |
| *Please briefly summarize the proposal you would like to submit by addressing the following aspects: 1) Current situation and problem description, 2) Solution/intended approach, 3) Development steps, 4) Expected outcome and fit in current practice. Max. 200 words.*Fill in text here…. |

**Status Biomarker**

|  |
| --- |
| *Briefly describe the current development status of the biomarker. You may want to include answers to the following questions in your explanation: Has the biomarker already been tested in a clinical setting/prospective study? Is the biomarker already in a format that can be implemented in clinical practice? Have you already taken steps towards commercialization and/or implementation of the biomarker? Max. 200 words.*Fill in text here…. |

**References (optional)**

Fill in text here….